Bioasis Technologies (Bioasis Technologies) Total Current Assets : $0.29 Mil (As of Nov. 2022)

View and export this data going back to 2009. Start your Free Trial

What is Bioasis Technologies Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Bioasis Technologies's total current assets for the quarter that ended in Nov. 2022 was $0.29 Mil.

Bioasis Technologies Total Current Assets Historical Data

The historical data trend for Bioasis Technologies's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioasis Technologies Total Current Assets Chart

Bioasis Technologies Annual Data

Trend

Feb13

Feb14

Feb15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Total Current Assets

Get a 7-Day Free Trial

0.63

1.05

0.49

2.41

1.66

Bioasis Technologies Quarterly Data
	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22
Total Current Assets	Get a 7-Day Free Trial															2.25	1.66	0.89	0.70	0.29

Bioasis Technologies Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Bioasis Technologies's Total Current Assets for the fiscal year that ended in Feb. 2022 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	1.362	+	0.077	+	0	+	0.219
	=	1.66

Bioasis Technologies's Total Current Assets for the quarter that ended in Nov. 2022 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0.117	+	0.01	+	0	+	0.158
	=	0.29

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Bioasis Technologies (OTCPK:BIOAF) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Bioasis Technologies's Liquidation Value for the quarter that ended in Nov. 2022 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.117	-	3.314	+	0.75 * 0.01	+	0.5 * 0
=	-3.19

Bioasis Technologies Total Current Assets Related Terms

Thank you for viewing the detailed overview of Bioasis Technologies's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioasis Technologies (Bioasis Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioasis Technologies Inc (OTCPK:BIOAF) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

157 Church Street, 19th Floor, New Haven, CT, USA, 06510

Website

https://www.bioasis.us

Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.